{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:50:20Z","timestamp":1791370220093,"version":"4.3.1"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institutes of Health AIM-AHEAD Research Fellowship","award":["1OT2OD032581-04"],"award-info":[{"award-number":["1OT2OD032581-04"]}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K01DK142045"],"award-info":[{"award-number":["K01DK142045"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02431-y","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:59:31Z","timestamp":1791367171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2113-0897","authenticated-orcid":false,"given":"Andre H","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boomer","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amara","family":"Sarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrant","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farideh","family":"Akramimoghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshozimhede","family":"Iyalomhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Katkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarya","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-1486","authenticated-orcid":false,"given":"Polina","family":"Kukhareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2431_CR1","doi-asserted-by":"publisher","first-page":"100527","DOI":"10.1016\/j.ajpc.2023.100527","volume":"15","author":"A Abovich","year":"2023","unstructured":"Abovich A, Matasic DS, Cardoso R, Ndumele CE, Blumenthal RS, Blankstein R, et al. The AHA\/ACC\/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention. Am J Prev Cardiol. 2023;15:100527. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100527.","journal-title":"Am J Prev Cardiol"},{"issue":"4S","key":"2431_CR2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"2431_CR3","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes*","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183\u2013215. https:\/\/doi.org\/10.2337\/dc26-S009.","journal-title":"Diabetes Care"},{"issue":"3","key":"2431_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2025.5305","volume":"11","author":"LA Mounsey","year":"2026","unstructured":"Mounsey LA, Chitsazan M, Shi I, Ribeiro PH, Parekh JK, Roshandelpoor A, et al. Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. JAMA Cardiol. 2026;11(3):250\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2025.5305.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2431_CR5","doi-asserted-by":"publisher","first-page":"108204","DOI":"10.1016\/j.jdiacomp.2022.108204","volume":"36","author":"CP Limonte","year":"2022","unstructured":"Limonte CP, Hall YN, Trikudanathan S, Tuttle KR, Hirsch IB, de Boer IH, et al. Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complications. 2022;36(6):108204. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108204.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"2431_CR6","doi-asserted-by":"publisher","first-page":"e2035792","DOI":"10.1001\/jamanetworkopen.2020.35792","volume":"4","author":"RG McCoy","year":"2021","unstructured":"McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, et al. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Netw Open. 2021;4(2):e2035792. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.35792.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2431_CR7","doi-asserted-by":"publisher","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, et al. Association of Race\/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Netw Open. 2021;4(4):e216139. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6139.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2431_CR8","doi-asserted-by":"publisher","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","volume":"2","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.4182.","journal-title":"JAMA Health Forum"},{"issue":"2","key":"2431_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3122\/jabfm.2022.02.210360","volume":"35","author":"AS Ali","year":"2022","unstructured":"Ali AS, Khan M, Ortega D, Jaffery S, Lamerato LE, Budzynska K. Prescription Patterns of Novel Antihyperglycemic Medications. J Am Board Fam Med JABFM. 2022;35(2):255\u201364. https:\/\/doi.org\/10.3122\/jabfm.2022.02.210360.","journal-title":"J Am Board Fam Med JABFM"},{"issue":"3","key":"2431_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/03007995.2024.2303413","volume":"40","author":"BG Mittman","year":"2024","unstructured":"Mittman BG, Le P, Payne JY, Ayers G, Rothberg MB. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020. Curr Med Res Opin. 2024;40(3):377\u201383. https:\/\/doi.org\/10.1080\/03007995.2024.2303413.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2431_CR11","doi-asserted-by":"publisher","first-page":"mzaf131","DOI":"10.1093\/intqhc\/mzaf131","volume":"38","author":"V Vaidya","year":"2026","unstructured":"Vaidya V, Estep S, Gupte R. Income disparities and accessibility to Semaglutide: implications for diabetes management and policy reform. Int J Qual Health Care J Int Soc Qual Health Care. 2026;38(1):mzaf131. https:\/\/doi.org\/10.1093\/intqhc\/mzaf131.","journal-title":"Int J Qual Health Care J Int Soc Qual Health Care"},{"issue":"1","key":"2431_CR12","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57349.","journal-title":"JAMA Netw Open"},{"key":"2431_CR13","doi-asserted-by":"publisher","first-page":"110151","DOI":"10.1016\/j.annepidem.2026.110151","volume":"122","author":"J Sanborn","year":"2026","unstructured":"Sanborn J, Fleary SA, Nash D, Penrose K, Parcesepe AM, Piltch-Loeb R, et al. GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort. Ann Epidemiol. 2026;122:110151. https:\/\/doi.org\/10.1016\/j.annepidem.2026.110151.","journal-title":"Ann Epidemiol"},{"key":"2431_CR14","unstructured":"Montero A, Kearney A, Mulugeta M, Kirzinger A, Hamel L. KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use [Internet]. KFF. 2025. https:\/\/www.kff.org\/public-opinion\/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use\/. Accessed 15 July 2026."},{"issue":"2","key":"2431_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/pharmacy13020046","volume":"13","author":"J Moore","year":"2025","unstructured":"Moore J, Iheme N, Rebold NS, Kusi H, Mere C, Nwaogwugwu U, et al. Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence. Pharmacy. 2025;13(2):46. https:\/\/doi.org\/10.3390\/pharmacy13020046.","journal-title":"Pharmacy"},{"issue":"2","key":"2431_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10557-022-07403-2","volume":"38","author":"D Devineni","year":"2024","unstructured":"Devineni D, Akbarpour M, Gong Y, Wong ND. Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. Cardiovasc Drugs Ther. 2024;38(2):347\u201357. https:\/\/doi.org\/10.1007\/s10557-022-07403-2.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2431_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.amjcard.2025.08.028","volume":"256","author":"Z Bashir","year":"2025","unstructured":"Bashir Z, Saxena R, Khalife W, Jneid H, Chatila K, Albaeni A. Predictors of Sodium Glucose Co-Transporter-2 Inhibitor Utilization in Elderly Heart Failure Patients: A Real-World Population-Level Dataset Analysis. Am J Cardiol. 2025;256:130\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2025.08.028.","journal-title":"Am J Cardiol"},{"issue":"6","key":"2431_CR18","doi-asserted-by":"publisher","first-page":"102224","DOI":"10.1016\/j.japh.2024.102224","volume":"64","author":"AM Pradhan","year":"2024","unstructured":"Pradhan AM, Lussier ME, Nguyen M, Voyce SJ, Wright EA. Qualitative evaluation to understand barriers and facilitators to prescribing angiotensin receptor-neprilysin inhibitors (ARNi) and sodium-glucose cotransporter inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF). J Am Pharm Assoc JAPhA. 2024;64(6):102224. https:\/\/doi.org\/10.1016\/j.japh.2024.102224.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"4","key":"2431_CR19","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1002\/osp4.783","volume":"10","author":"MA McVay","year":"2024","unstructured":"McVay MA, Moore WS, Wilkins FL, Jackson JR, Robinson MD. Patient perspectives on incretin-based weight loss medications and relationship with demographic factors. Obes Sci Pract. 2024;10(4):e783. https:\/\/doi.org\/10.1002\/osp4.783.","journal-title":"Obes Sci Pract"},{"key":"2431_CR20","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.ajpc.2025.100966","volume":"22","author":"DM Bolden","year":"2025","unstructured":"Bolden DM, Richardson V, Salahuddin T, Henderson K, Hess PL, Raghavan S, et al. Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. Am J Prev Cardiol. 2025;22:100966. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100966.","journal-title":"Am J Prev Cardiol"},{"key":"2431_CR21","doi-asserted-by":"publisher","first-page":"110233","DOI":"10.1016\/j.diabres.2022.110233","volume":"196","author":"EC Vasti","year":"2023","unstructured":"Vasti EC, Basina M, Calma J, Maron DJ, Rodriguez F, Sandhu AT. Disparities in adoption of new diabetic therapies with cardiovascular benefits. Diabetes Res Clin Pract. 2023;196:110233. https:\/\/doi.org\/10.1016\/j.diabres.2022.110233.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2431_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.18553\/jmcp.2026.32.1.14","volume":"32","author":"N Akpan","year":"2026","unstructured":"Akpan N, Zhou B, Rasu RS, Sambamoorthi U. Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States. J Manag Care Spec Pharm. 2026;32(1):14\u201326. https:\/\/doi.org\/10.18553\/jmcp.2026.32.1.14.","journal-title":"J Manag Care Spec Pharm"},{"key":"2431_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/2024.10.28.24316312","volume-title":"Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis","author":"PV Kukhareva","year":"2024","unstructured":"Kukhareva PV, Facelli JC, O\u2019Brien MJ, Gouripeddi R, Kawamoto K, Zhang Y, et al. Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. medRxiv: The Preprint Server for Health Sciences; 2024. https:\/\/doi.org\/10.1101\/2024.10.28.24316312."},{"key":"2431_CR24","doi-asserted-by":"publisher","first-page":"100455","DOI":"10.1016\/j.ahjo.2024.100455","volume":"46","author":"TK Reddy","year":"2024","unstructured":"Reddy TK, Villavaso CD, Pulapaka AV, Ferdinand KC. Achieving equitable access to incretin-based therapies in cardiovascular care. Am Heart J Plus Cardiol Res Pract. 2024;46:100455. https:\/\/doi.org\/10.1016\/j.ahjo.2024.100455.","journal-title":"Am Heart J Plus Cardiol Res Pract"},{"key":"2431_CR25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2431_CR26","doi-asserted-by":"publisher","unstructured":"Gartlehner G, Kugley S, Crotty K, Viswanathan M, Dobrescu A, Nussbaumer-Streit B, et al. . Artificial Intelligence-Assisted Data Extraction With a Large Language Model: A Study Within Reviews. Ann Intern Med. 2025;178(12):1763\u201371. https:\/\/doi.org\/10.7326\/ANNALS-25-00739","DOI":"10.7326\/ANNALS-25-00739"},{"issue":"1","key":"2431_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13012-019-0861-y","volume":"14","author":"EN Woodward","year":"2019","unstructured":"Woodward EN, Matthieu MM, Uchendu US, Rogal S, Kirchner JE. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci IS. 2019;14(1):26. https:\/\/doi.org\/10.1186\/s13012-019-0861-y.","journal-title":"Implement Sci IS"},{"issue":"4","key":"2431_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/oby.70152","volume":"34","author":"K Wasden","year":"2026","unstructured":"Wasden K, Sheu N, Medhati P, Tsai TC, Kim DW, Tavakkoli A, et al. Disparities in Prescription of Long-Acting GLP-1s. Obesity. 2026;34(4):961\u201371. https:\/\/doi.org\/10.1002\/oby.70152.","journal-title":"Obesity"},{"key":"2431_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usag142","author":"RL Corrado","year":"2026","unstructured":"Corrado RL, Meier M, Banaag A, Neuman T, Koehlmoos TP. Prevalence of Obesity Medications in the Military Health System: An Update from 2022. Mil Med. 2026. https:\/\/doi.org\/10.1093\/milmed\/usag142. usag142.","journal-title":"Mil Med"},{"issue":"4","key":"2431_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cardfail.2024.08.059","volume":"31","author":"S Agrawal","year":"2025","unstructured":"Agrawal S, Alhaddad Z, Nabia S, Rehman OU, Kiyani M, Kumar A, et al. Prescription Patterns in Management of Heart Failure and Its Association With Readmissions: A Retrospective Analysis. J Card Fail. 2025;31(4):635\u201345. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.059.","journal-title":"J Card Fail"},{"issue":"5","key":"2431_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.pcd.2024.07.003","volume":"18","author":"A Alshehri","year":"2024","unstructured":"Alshehri A, Guan D, Li P, Zhang Y, Ghayee HK, Jiao T, et al. Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005\u20132019. Prim Care Diabetes. 2024;18(5):561\u20133. https:\/\/doi.org\/10.1016\/j.pcd.2024.07.003.","journal-title":"Prim Care Diabetes"},{"key":"2431_CR32","doi-asserted-by":"publisher","first-page":"1537181","DOI":"10.3389\/fmed.2025.1537181","volume":"12","author":"AA Alsuhibani","year":"2025","unstructured":"Alsuhibani AA, Alrasheed MA, Alhomoud IS, Alsahali S, Almalki ZS, Guo JJ. Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023. Front Med. 2025;12:1537181. https:\/\/doi.org\/10.3389\/fmed.2025.1537181.","journal-title":"Front Med"},{"key":"2431_CR33","doi-asserted-by":"publisher","unstructured":"Antwi-Amoabeng D, Beutler BD, Ghuman J, Ulanja MB, Ghuman J, Gullapalli N, et al. Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes. Cureus. 2024;16(3). https:\/\/doi.org\/10.7759\/cureus.56845.","DOI":"10.7759\/cureus.56845"},{"issue":"15","key":"2431_CR34","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1177\/2047487317729252","volume":"24","author":"SV Arnold","year":"2017","unstructured":"Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR\u00ae Research to Practice project. Eur J Prev Cardiol. 2017;24(15):1637\u201345. https:\/\/doi.org\/10.1177\/2047487317729252.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"2431_CR35","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s11606-024-08961-x","volume":"39","author":"L Bepo","year":"2024","unstructured":"Bepo L, Nguyen OK, Makam AN. Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study. J Gen Intern Med. 2024;39(15):2987\u201394. https:\/\/doi.org\/10.1007\/s11606-024-08961-x.","journal-title":"J Gen Intern Med"},{"key":"2431_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ahj.2025.01.003","volume":"282","author":"AJ Blood","year":"2025","unstructured":"Blood AJ, Chang L-S, Colling C, Stern G, Gabovitch D, Zelle D, et al. Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies. Am Heart J. 2025;282:114\u201324. https:\/\/doi.org\/10.1016\/j.ahj.2025.01.003.","journal-title":"Am Heart J"},{"key":"2431_CR37","doi-asserted-by":"publisher","first-page":"e66400","DOI":"10.2196\/66400","volume":"27","author":"BE Bloom","year":"2025","unstructured":"Bloom BE, Bragg MA, Jay MR, Harel D, Cline C, Crowe M, et al. How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women\u2019s Health, Nontraditional Access, and Barriers to Access: Content Analysis. J Med Internet Res. 2025;27:e66400. https:\/\/doi.org\/10.2196\/66400.","journal-title":"J Med Internet Res"},{"issue":"5","key":"2431_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.pcd.2025.05.011","volume":"19","author":"VJ Brady","year":"2025","unstructured":"Brady VJ, Akyirem S, Padhye N. Racial and ethnic differences in prescribing antihyperglycemic medications to persons with type 2 diabetes: An all of us cohort study. Prim Care Diabetes. 2025;19(5):504\u201311. https:\/\/doi.org\/10.1016\/j.pcd.2025.05.011.","journal-title":"Prim Care Diabetes"},{"issue":"11","key":"2431_CR39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.18553\/jmcp.2024.30.11.1298","volume":"30","author":"W-H Chen","year":"2024","unstructured":"Chen W-H, Li Y, Chen A, Allen JM, Guo Y, Bilello L, et al. Social determinants of health and newer glucose-lowering drugs adoption among US Medicare beneficiaries with type 2 diabetes. J Manag Care Spec Pharm. 2024;30(11):1298\u2013307. https:\/\/doi.org\/10.18553\/jmcp.2024.30.11.1298.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2431_CR40","doi-asserted-by":"publisher","first-page":"e0297208","DOI":"10.1371\/journal.pone.0297208","volume":"19","author":"W-H Chen","year":"2024","unstructured":"Chen W-H, Li Y, Yang L, Allen JM, Shao H, Donahoo WT, et al. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes. PLoS ONE. 2024;19(1):e0297208. https:\/\/doi.org\/10.1371\/journal.pone.0297208.","journal-title":"PLoS ONE"},{"issue":"1","key":"2431_CR41","doi-asserted-by":"publisher","first-page":"e3531705","DOI":"10.1155\/jdr\/3531705","volume":"2026","author":"HN Chen","year":"2026","unstructured":"Chen HN, Weiner M, Wolfson J, Hannon T, Balius P, Schleyer T. Long-Term Glycemic Control and Pharmacotherapy in Type 2 Diabetes Mellitus: A Descriptive Analysis of 10-Year Trends in a Statewide Sample. J Diabetes Res. 2026;2026(1):e3531705. https:\/\/doi.org\/10.1155\/jdr\/3531705.","journal-title":"J Diabetes Res"},{"issue":"1","key":"2431_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/dc22-0383","volume":"46","author":"SJ Cromer","year":"2023","unstructured":"Cromer SJ, Lauffenburger JC, Levin R, Patorno E. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care. 2023;46(1):65\u201374. https:\/\/doi.org\/10.2337\/dc22-0383.","journal-title":"Diabetes Care"},{"issue":"2","key":"2431_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2337\/dc25-1619","volume":"49","author":"SRR Decker","year":"2026","unstructured":"Decker SRR, Chaudhary RS, Inoue K, Song Y, Ndumele CE, Khan SS, et al. Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. 2026;49(2):277\u201381. https:\/\/doi.org\/10.2337\/dc25-1619.","journal-title":"Diabetes Care"},{"issue":"1","key":"2431_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40842-026-00280-w","volume":"12","author":"Q Ding","year":"2026","unstructured":"Ding Q, Sico JJ, Perkins AJ, Myers LJ, Daggy JK, Sexson A, et al. Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients. Cardiovasc Diabetol Endocrinol Rep. 2026;12(1):11. https:\/\/doi.org\/10.1186\/s40842-026-00280-w.","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"issue":"1","key":"2431_CR45","doi-asserted-by":"publisher","first-page":"2441220","DOI":"10.1080\/20523211.2024.2441220","volume":"18","author":"MJ DiStefano","year":"2025","unstructured":"DiStefano MJ, Dardouri M, Moore GD, Saseen JJ, Nair KV. Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado. J Pharm Policy Pract. 2025;18(1):2441220. https:\/\/doi.org\/10.1080\/20523211.2024.2441220.","journal-title":"J Pharm Policy Pract"},{"issue":"4","key":"2431_CR46","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.mayocp.2024.08.026","volume":"100","author":"DL Dixon","year":"2025","unstructured":"Dixon DL, Salgado TM, Robinson A, Carbone S, Wagner TD, Hyder H, et al. Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits. Mayo Clin Proc. 2025;100(4):647\u201356. https:\/\/doi.org\/10.1016\/j.mayocp.2024.08.026.","journal-title":"Mayo Clin Proc"},{"key":"2431_CR47","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.lana.2021.100111","volume":"6","author":"A Elhussein","year":"2022","unstructured":"Elhussein A, Anderson A, Bancks MP, Coday M, Knowler WC, Peters A, et al. Racial\/ethnic and socioeconomic disparities in the use of newer diabetes medications in the Look AHEAD study. Lancet Reg Health Am. 2022;6:100111. https:\/\/doi.org\/10.1016\/j.lana.2021.100111.","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"2431_CR48","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2337\/dc21-1178","volume":"45","author":"UR Essien","year":"2022","unstructured":"Essien UR, Tang Y, Figueroa JF, Litam TMA, Tang F, Jones PG, et al. Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. Diabetes Care. 2022;45(7):1549\u201357. https:\/\/doi.org\/10.2337\/dc21-1178.","journal-title":"Diabetes Care"},{"issue":"6","key":"2431_CR49","doi-asserted-by":"publisher","first-page":"e2316290","DOI":"10.1001\/jamanetworkopen.2023.16290","volume":"6","author":"UR Essien","year":"2023","unstructured":"Essien UR, Singh B, Swabe G, Johnson AE, Eberly LA, Wadhera RK, et al. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes. JAMA Netw Open. 2023;6(6):e2316290. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.16290.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2431_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s11695-024-07181-w","volume":"34","author":"SA Firkins","year":"2024","unstructured":"Firkins SA, Chittajallu V, Flora B, Yoo H, Simons-Linares R. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database. Obes Surg. 2024;34(5):1415\u201324. https:\/\/doi.org\/10.1007\/s11695-024-07181-w.","journal-title":"Obes Surg"},{"issue":"3","key":"2431_CR51","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1002\/osp4.756","volume":"10","author":"WT Garvey","year":"2024","unstructured":"Garvey WT, Mahle CD, Bell T, Kushner RF. Healthcare professionals\u2019 perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists. Obes Sci Pract. 2024;10(3):e756. https:\/\/doi.org\/10.1002\/osp4.756.","journal-title":"Obes Sci Pract"},{"issue":"5","key":"2431_CR52","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/dom.15473","volume":"26","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, Sullivan E, Le P, Rothberg MB. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills. Diabetes Obes Metab. 2024;26(5):1687\u201396. https:\/\/doi.org\/10.1111\/dom.15473.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2431_CR53","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.18553\/jmcp.2025.31.12.1311","volume":"31","author":"KL Gavin","year":"2025","unstructured":"Gavin KL, Amjad R, Makris V, Neuner JM. Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin. J Manag Care Spec Pharm. 2025;31(12):1311\u20139. https:\/\/doi.org\/10.18553\/jmcp.2025.31.12.1311.","journal-title":"J Manag Care Spec Pharm"},{"key":"2431_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.amjcard.2022.10.041","volume":"189","author":"HC Gay","year":"2023","unstructured":"Gay HC, Yu J, Persell SD, Linder JA, Srivastava A, Isakova T, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease. Am J Cardiol. 2023;189:121\u201330. https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.041.","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"2431_CR55","doi-asserted-by":"publisher","first-page":"e002135","DOI":"10.1136\/bmjdrc-2021-002135","volume":"9","author":"J Gemelas","year":"2021","unstructured":"Gemelas J, Marino M, Valenzuela S, Schmidt T, Suchocki A, Huguet N. Changes in diabetes prescription patterns following Affordable Care Act Medicaid expansion. BMJ Open Diabetes Res Care. 2021;9(Suppl 1):e002135. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002135.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"2431_CR56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12872-024-03961-5","volume":"24","author":"J Gonzalez","year":"2024","unstructured":"Gonzalez J, Dave CV. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013\u20132021. BMC Cardiovasc Disord. 2024;24(1):285. https:\/\/doi.org\/10.1186\/s12872-024-03961-5.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2431_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/j.ajkd.2022.11.017","volume":"82","author":"LP Gregg","year":"2023","unstructured":"Gregg LP, Ramsey DJ, Akeroyd JM, Jafry SA, Matheny ME, Virani SS, et al. Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Am J Kidney Dis Off J Natl Kidney Found. 2023;82(1):53\u2013e621. https:\/\/doi.org\/10.1053\/j.ajkd.2022.11.017.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"2431_CR58","doi-asserted-by":"publisher","first-page":"100370","DOI":"10.1016\/j.ajpc.2022.100370","volume":"11","author":"J Hanna","year":"2022","unstructured":"Hanna J, Nargesi AA, Essien UR, Sangha V, Lin Z, Krumholz HM, et al. County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries. Am J Prev Cardiol. 2022;11:100370. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100370.","journal-title":"Am J Prev Cardiol"},{"issue":"10","key":"2431_CR59","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2337\/dc21-0529","volume":"44","author":"ST Harris","year":"2021","unstructured":"Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. Diabetes Care. 2021;44(10):2293\u2013301. https:\/\/doi.org\/10.2337\/dc21-0529.","journal-title":"Diabetes Care"},{"issue":"12","key":"2431_CR60","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/jama.2024.18219","volume":"332","author":"TA Hegland","year":"2024","unstructured":"Hegland TA, Fang Z, Bucher K. GLP-1 Medication Use for Type 2 Diabetes Has Soared. JAMA. 2024;332(12):952\u20133. https:\/\/doi.org\/10.1001\/jama.2024.18219.","journal-title":"JAMA"},{"issue":"10","key":"2431_CR61","doi-asserted-by":"publisher","first-page":"e70227","DOI":"10.1002\/pds.70227","volume":"34","author":"N Hendrix","year":"2025","unstructured":"Hendrix N, Vel\u00e1squez EE, Pham H, Bazemore A. Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. Pharmacoepidemiol Drug Saf. 2025;34(10):e70227. https:\/\/doi.org\/10.1002\/pds.70227.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2431_CR62","doi-asserted-by":"publisher","unstructured":"Hsiao AL, Agwagom JS, Tian MY, Arnet RE, Garasich FA, Camacho OE, et al. Increases but pronounced state-level disparities in semaglutide prescribing to Medicaid patients from 2018 to 2022 [Internet]. medRxiv. 2025;2025073125332171. https:\/\/doi.org\/10.1101\/2025.07.31.25332171.","DOI":"10.1101\/2025.07.31.25332171"},{"key":"2431_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/DHPS.S496619","volume":"17","author":"S Hu","year":"2025","unstructured":"Hu S, Zanwar PP, Jenkins T, Sevak RJ, Jasti BR. Comparing Out-of-Pocket Costs and Health-Related Quality of Life Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes. Drug Healthc Patient Saf. 2025;17:121\u201334. https:\/\/doi.org\/10.2147\/DHPS.S496619.","journal-title":"Drug Healthc Patient Saf"},{"issue":"6","key":"2431_CR64","doi-asserted-by":"publisher","first-page":"651","DOI":"10.18553\/jmcp.2026.32.6.651","volume":"32","author":"H Huddleston","year":"2026","unstructured":"Huddleston H, Martinez J, Cook J, Trapp M, Chen N-C, Schwander K, et al. Assessing the impact of pharmacist-led interventions on glucagon-like peptide 1 receptor agonist access and treatment outcomes. J Manag Care Spec Pharm. 2026;32(6):651\u20139. https:\/\/doi.org\/10.18553\/jmcp.2026.32.6.651.","journal-title":"J Manag Care Spec Pharm"},{"key":"2431_CR65","first-page":"10","volume":"8","author":"AL Hume","year":"2022","unstructured":"Hume AL, Osundolire S, Mbrah AK, Nunes AP, Lapane KL. Antihyperglycemic Drug Use in Long-Stay Nursing Home Residents with Diabetes Mellitus. J Nurs Home Res Sci. 2022;8:10\u20139.","journal-title":"J Nurs Home Res Sci"},{"issue":"1","key":"2431_CR66","doi-asserted-by":"publisher","first-page":"e012357","DOI":"10.1161\/CIRCHEARTFAILURE.124.012357","volume":"18","author":"JA Jacobs","year":"2025","unstructured":"Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, et al. Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. Circ Heart Fail. 2025;18(1):e012357. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012357.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2431_CR67","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jamacardio.2026.0375","volume":"11","author":"JA Jacobs","year":"2026","unstructured":"Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, et al. Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2026;11(6):506\u201314. https:\/\/doi.org\/10.1001\/jamacardio.2026.0375.","journal-title":"JAMA Cardiol"},{"key":"2431_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-026-10408-4","author":"M Jacobs","year":"2026","unstructured":"Jacobs M, Fang Q, Ellis C. Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017\u20132023: Demographic, Income, and Insurance Associations. J Gen Intern Med. 2026. https:\/\/doi.org\/10.1007\/s11606-026-10408-4.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"2431_CR69","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.18553\/jmcp.2023.23083","volume":"29","author":"H Kan","year":"2023","unstructured":"Kan H, Bae JP, Dunn JP, Buysman EK, Gronroos NN, Swindle JP, et al. Real-world primary nonadherence to antiobesity medications. J Manag Care Spec Pharm. 2023;29(10):1099\u2013108. https:\/\/doi.org\/10.18553\/jmcp.2023.23083.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2431_CR70","doi-asserted-by":"publisher","first-page":"102309","DOI":"10.1016\/j.japh.2024.102309","volume":"65","author":"K Kido","year":"2025","unstructured":"Kido K, Fang W, Becher K, Carey B, Sokos G. Implementing a telemedicine-led heart failure medication regimen optimization clinic in medically underserved heart failure populations. J Am Pharm Assoc JAPhA. 2025;65(1):102309. https:\/\/doi.org\/10.1016\/j.japh.2024.102309.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"24","key":"2431_CR71","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2025.4735","volume":"333","author":"C Kim","year":"2025","unstructured":"Kim C, Ross JS, Jastreboff AM, Meeker D, Freedman H, Krumholz HM, et al. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US. JAMA. 2025;333(24):2203\u20136. https:\/\/doi.org\/10.1001\/jama.2025.4735.","journal-title":"JAMA"},{"issue":"10","key":"2431_CR72","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jamasurg.2025.3089","volume":"160","author":"M Kim","year":"2025","unstructured":"Kim M, Schweitzer MA, Kim JS, Alexander GC, Mehta HB. Use of Glucagon-Like Peptide-1 Agonists Among Individuals Undergoing Bariatric Surgery in the US. JAMA Surg. 2025;160(10):1058\u201366. https:\/\/doi.org\/10.1001\/jamasurg.2025.3089.","journal-title":"JAMA Surg"},{"issue":"5","key":"2431_CR73","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-020-01279-y","volume":"80","author":"DN Koye","year":"2020","unstructured":"Koye DN, Montvida O, Paul SK. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study. Drugs. 2020;80(5):477\u201387. https:\/\/doi.org\/10.1007\/s40265-020-01279-y.","journal-title":"Drugs"},{"issue":"9","key":"2431_CR74","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jama.2022.13885","volume":"328","author":"JA Lamprea-Montealegre","year":"2022","unstructured":"Lamprea-Montealegre JA, Madden E, Tummalapalli SL, Peralta C, Neilands TB, Garcia PK, et al. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022;328(9):861\u201371. https:\/\/doi.org\/10.1001\/jama.2022.13885.","journal-title":"JAMA"},{"issue":"4","key":"2431_CR75","doi-asserted-by":"publisher","first-page":"e15257","DOI":"10.1111\/ctr.15257","volume":"38","author":"KL Lentine","year":"2024","unstructured":"Lentine KL, Miyata KN, Lam NN, Joseph C, McAdams-DeMarco M, Bae S, et al. Sociodemographic disparities in sodium-glucose cotransporter-2 inhibitor use among US kidney transplant recipients: An observational study of real-world pharmacy records. Clin Transpl. 2024;38(4):e15257. https:\/\/doi.org\/10.1111\/ctr.15257.","journal-title":"Clin Transpl"},{"issue":"7","key":"2431_CR76","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/annalsats\/aaoag047","volume":"23","author":"AG Leonhard","year":"2026","unstructured":"Leonhard AG, Josey K, Castaneda JM, Chee M, Duan KI, Nadeem H, et al. Receipt of glucagon-like peptide-1 receptor agonists among rural patients with obstructive sleep apnea and excess weight. Ann Am Thorac Soc. 2026;23(7):1087\u201396. https:\/\/doi.org\/10.1093\/annalsats\/aaoag047.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"2431_CR77","doi-asserted-by":"publisher","first-page":"e098899","DOI":"10.1136\/bmjopen-2025-098899","volume":"15","author":"R Li","year":"2025","unstructured":"Li R, Li S, Xiao N, Pan S, Yang J, Liu G, et al. Cost-related non-adherence in US adults with heart failure: a repeated cross-sectional analysis of the medical expenditure panel survey, 2012 to 2021. BMJ Open. 2025;15(5):e098899. https:\/\/doi.org\/10.1136\/bmjopen-2025-098899.","journal-title":"BMJ Open"},{"issue":"2","key":"2431_CR78","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/dom.14894","volume":"25","author":"P Li","year":"2023","unstructured":"Li P, Zhang P, Guan D, Guo J, Zhang Y, Pavkov ME, et al. Changes in racial and ethnic disparities in glucose-lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005\u20132018. Diabetes Obes Metab. 2023;25(2):516\u201325. https:\/\/doi.org\/10.1111\/dom.14894.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2431_CR79","doi-asserted-by":"publisher","first-page":"e2529842","DOI":"10.1001\/jamanetworkopen.2025.29842","volume":"8","author":"X Liu","year":"2025","unstructured":"Liu X, Lu CA, Shih Y-CT, Jiang C. Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans. JAMA Netw Open. 2025;8(8):e2529842. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.29842.","journal-title":"JAMA Netw Open"},{"key":"2431_CR80","doi-asserted-by":"publisher","DOI":"10.1111\/dom.71013","author":"TS Lux","year":"2026","unstructured":"Lux TS, Lee D, Phillips JM, Facelli JC, Malone DC, Wahl M, et al. Prescribing Trajectories in Type 2 Diabetes in the United States, 2019\u20132024. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.71013.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2431_CR81","doi-asserted-by":"publisher","first-page":"808","DOI":"10.7326\/ANNALS-24-01449","volume":"178","author":"AN Makam","year":"2025","unstructured":"Makam AN, Bailey L, Anderson N, Bellitti K, Skinner S, Nguyen OK. Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program. Ann Intern Med. 2025;178(6):808\u201318. https:\/\/doi.org\/10.7326\/ANNALS-24-01449.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2431_CR82","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1060028014563951","volume":"49","author":"ZA Marcum","year":"2015","unstructured":"Marcum ZA, Driessen J, Thorpe CT, Donohue JM, Gellad WF. Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics. Ann Pharmacother. 2015;49(3):285\u201392. https:\/\/doi.org\/10.1177\/1060028014563951.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2431_CR83","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1089\/dia.2019.0213","volume":"21","author":"RG McCoy","year":"2019","unstructured":"McCoy RG, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, et al. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technol Ther. 2019;21(12):702\u201312. https:\/\/doi.org\/10.1089\/dia.2019.0213.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"2431_CR84","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12020-021-02710-4","volume":"73","author":"RG McCoy","year":"2021","unstructured":"McCoy RG, Van Houten HK, Dunlay SM, Yao X, Dempsey T, Noseworthy PA, et al. Race and sex differences in the initiation of diabetes drugs by privately insured US adults. Endocrine. 2021;73(2):480\u20134. https:\/\/doi.org\/10.1007\/s12020-021-02710-4.","journal-title":"Endocrine"},{"issue":"20","key":"2431_CR85","doi-asserted-by":"publisher","first-page":"e043610","DOI":"10.1161\/JAHA.125.043610","volume":"14","author":"A Mukhopadhyay","year":"2025","unstructured":"Mukhopadhyay A, Ladino N, Stokes T, Narendrula A, Katz SD, Reynolds HR, et al. Impact of Heart Failure Guideline Publication on Medicare Drug Coverage Policies: A Quasi-Experimental Analysis. J Am Heart Assoc. 2025;14(20):e043610. https:\/\/doi.org\/10.1161\/JAHA.125.043610.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2431_CR86","doi-asserted-by":"publisher","first-page":"102583","DOI":"10.1016\/j.jacadv.2025.102583","volume":"5","author":"A Mukhopadhyay","year":"2026","unstructured":"Mukhopadhyay A, Adhikari S, Li X, Kazi DS, Berman AN, Kronish I, et al. Prior Authorization Requirements and Prescription Fill Patterns Among Patients With Heart Failure. JACC Adv. 2026;5(2):102583. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102583.","journal-title":"JACC Adv"},{"issue":"2","key":"2431_CR87","doi-asserted-by":"publisher","first-page":"e2148030","DOI":"10.1001\/jamanetworkopen.2021.48030","volume":"5","author":"AJ Nelson","year":"2022","unstructured":"Nelson AJ, O\u2019Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG, et al. Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2022;5(2):e2148030. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.48030.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2431_CR88","doi-asserted-by":"publisher","first-page":"699","DOI":"10.18553\/jmcp.2023.29.6.699","volume":"29","author":"DO Ogunsanmi","year":"2023","unstructured":"Ogunsanmi DO, Harrison AT, Pakker AR, Kovesdy CP, Bailey JE, Surbhi S. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations. J Manag Care Spec Pharm. 2023;29(6):699\u2013711. https:\/\/doi.org\/10.18553\/jmcp.2023.29.6.699.","journal-title":"J Manag Care Spec Pharm"},{"issue":"15","key":"2431_CR89","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jama.2023.2854","volume":"329","author":"NJ Pagidipati","year":"2023","unstructured":"Pagidipati NJ, Nelson AJ, Kaltenbach LA, Leyva M, McGuire DK, Pop-Busui R, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2023;329(15):1261\u201370. https:\/\/doi.org\/10.1001\/jama.2023.2854.","journal-title":"JAMA"},{"issue":"43","key":"2431_CR90","doi-asserted-by":"publisher","first-page":"e2412872121","DOI":"10.1073\/pnas.2412872121","volume":"121","author":"A Pandey","year":"2024","unstructured":"Pandey A, Ye Y, Wells CR, Singer BH, Galvani AP. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proc Natl Acad Sci U S A. 2024;121(43):e2412872121. https:\/\/doi.org\/10.1073\/pnas.2412872121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2431_CR91","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamacardio.2023.1266","volume":"8","author":"JB Pierce","year":"2023","unstructured":"Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, et al. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023;8(7):652\u201361. https:\/\/doi.org\/10.1001\/jamacardio.2023.1266.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2431_CR92","doi-asserted-by":"publisher","first-page":"e2455222","DOI":"10.1001\/jamanetworkopen.2024.55222","volume":"8","author":"MI Podolsky","year":"2025","unstructured":"Podolsky MI, Raquib R, Shafer PR, Hempstead K, Ellis RP, Stokes AC. Factors Associated With Semaglutide Initiation Among Adults With Obesity. JAMA Netw Open. 2025;8(1):e2455222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.55222.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2431_CR93","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1111\/dom.16318","volume":"27","author":"RM Radwan","year":"2025","unstructured":"Radwan RM, Lee YA, Kotecha P, Wright DR, Hernandez I, Ramon R, et al. Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment. Diabetes Obes Metab. 2025;27(6):3113\u201323. https:\/\/doi.org\/10.1111\/dom.16318.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2431_CR94","doi-asserted-by":"publisher","first-page":"e012547","DOI":"10.1161\/CIRCHEARTFAILURE.124.012547","volume":"18","author":"AJ Sauer","year":"2025","unstructured":"Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, et al. Multiregional Implementation Initiative\u2019s Impact on Guideline-Based Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF. Circ Heart Fail. 2025;18(5):e012547. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012547.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"2431_CR95","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2337\/dc20-2926","volume":"44","author":"H Shin","year":"2021","unstructured":"Shin H, Schneeweiss S, Glynn RJ, Patorno E. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021;44(8):1774\u201382. https:\/\/doi.org\/10.2337\/dc20-2926.","journal-title":"Diabetes Care"},{"issue":"5","key":"2431_CR96","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/pds.5406","volume":"31","author":"H Shin","year":"2022","unstructured":"Shin H, Schneeweiss S, Glynn RJ, Patorno E. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiol Drug Saf. 2022;31(5):566\u201376. https:\/\/doi.org\/10.1002\/pds.5406.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2431_CR97","doi-asserted-by":"publisher","first-page":"100100","DOI":"10.1016\/j.ajmo.2025.100100","volume":"13","author":"KJ Spinelli","year":"2025","unstructured":"Spinelli KJ, Oakes AH, Chiu S-T, Imboden MT, Miller A, Jain S, et al. Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists. Am J Med Open. 2025;13:100100. https:\/\/doi.org\/10.1016\/j.ajmo.2025.100100.","journal-title":"Am J Med Open"},{"issue":"1","key":"2431_CR98","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11606-025-09784-0","volume":"41","author":"K Steiger","year":"2026","unstructured":"Steiger K, Swarna KS, Herrin J, McCoy RG. Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012\u20132021. J Gen Intern Med. 2026;41(1):126\u201333. https:\/\/doi.org\/10.1007\/s11606-025-09784-0.","journal-title":"J Gen Intern Med"},{"key":"2431_CR99","doi-asserted-by":"publisher","first-page":"107300","DOI":"10.1016\/j.ahj.2025.107300","volume":"293","author":"AB Steverson","year":"2026","unstructured":"Steverson AB, Fan J, Din N, Kalwani N, Varshney AS, Verma A, et al. Differences in guideline directed medical therapy for rural and non-rural Veterans with heart failure with reduced ejection fraction. Am Heart J. 2026;293:107300. https:\/\/doi.org\/10.1016\/j.ahj.2025.107300.","journal-title":"Am Heart J"},{"issue":"5","key":"2431_CR100","doi-asserted-by":"publisher","first-page":"e013835","DOI":"10.1161\/CIRCHEARTFAILURE.125.013835","volume":"19","author":"AB Tang","year":"2026","unstructured":"Tang AB, Li S, Li Y, Zhao J, Thomas K, Lewsey SC, et al. Improving Heart Failure Quality of Care Over the First Twenty Years: The Get With The Guidelines-Heart Failure Program. Circ Heart Fail. 2026;19(5):e013835. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.125.013835.","journal-title":"Circ Heart Fail"},{"issue":"3","key":"2431_CR101","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.124.068962","volume":"150","author":"M Tannu","year":"2024","unstructured":"Tannu M, Kaltenbach L, Pagidipati NJ, McGuire DK, Aroda VR, Pop-Busui R, et al. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial. Circulation. 2024;150(3):180\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068962.","journal-title":"Circulation"},{"issue":"1","key":"2431_CR102","doi-asserted-by":"publisher","first-page":"e77159","DOI":"10.7759\/cureus.77159","volume":"17","author":"S Taylor","year":"2025","unstructured":"Taylor S, Zinabu SW, McMillan E, Ocampo E, Edmonds A, Lyles S, et al. Breaking Barriers: Tackling Racial and Socioeconomic Disparities in the Prescription of Life-Saving SGLT2 Inhibitors for Proteinuria. Cureus. 2025;17(1):e77159. https:\/\/doi.org\/10.7759\/cureus.77159.","journal-title":"Cureus"},{"issue":"5","key":"2431_CR103","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1111\/dom.70579","volume":"28","author":"J Van Laren","year":"2026","unstructured":"Van Laren J, Friesleben C, Gershovich O, Helm L, Patel RJ, Delate T. Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist. Diabetes Obes Metab. 2026;28(5):3965\u201373. https:\/\/doi.org\/10.1111\/dom.70579.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2431_CR104","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00125-024-06321-2","volume":"68","author":"E Wang","year":"2025","unstructured":"Wang E, Patorno E, Khosrow-Khavar F, Crystal S, Dave CV. Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013\u20132019. Diabetologia. 2025;68(1):94\u2013104. https:\/\/doi.org\/10.1007\/s00125-024-06321-2.","journal-title":"Diabetologia"},{"issue":"10","key":"2431_CR105","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.18553\/jmcp.2025.31.10.1029","volume":"31","author":"J Wu","year":"2025","unstructured":"Wu J, Perez A, Sullivan PW. Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes. J Manag Care Spec Pharm. 2025;31(10):1029\u201338. https:\/\/doi.org\/10.18553\/jmcp.2025.31.10.1029.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"2431_CR106","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.18553\/jmcp.2023.29.11.1242","volume":"29","author":"L Yang","year":"2023","unstructured":"Yang L, Gabriel N, Bian J, Bilello LA, Wright DR, Hernandez I, et al. Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis. J Manag Care Spec Pharm. 2023;29(11):1242\u201351. https:\/\/doi.org\/10.18553\/jmcp.2023.29.11.1242.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2431_CR107","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jamda.2023.06.033","volume":"25","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zullo AR, Hayes KKN, Kim DH, Lee Y, Daiello LA, et al. Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents. J Am Med Dir Assoc. 2024;25(3):454\u20138. https:\/\/doi.org\/10.1016\/j.jamda.2023.06.033.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"2431_CR108","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s40615-025-02388-8","volume":"13","author":"P Zhang","year":"2026","unstructured":"Zhang P, Lobo JM, Sohn M-W, Balkrishnan R, Anderson R, McCall A, et al. Disparities in Antidiabetic Medication Discontinuation Between Non-Hispanic White and Black Beneficiaries in Medicare Across Diabetes Belt and Surrounding Area. J Racial Ethn Health Disparities. 2026;13(3):1950\u201360. https:\/\/doi.org\/10.1007\/s40615-025-02388-8.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"2431_CR109","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.xkme.2022.100564","volume":"5","author":"JZ Zhao","year":"2023","unstructured":"Zhao JZ, Weinhandl ED, Carlson AM, St Peter WL. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States. Kidney Med. 2023;5(1):100564. https:\/\/doi.org\/10.1016\/j.xkme.2022.100564.","journal-title":"Kidney Med"},{"issue":"1","key":"2431_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2337\/ds23-0075","volume":"38","author":"B Zhu","year":"2025","unstructured":"Zhu B, Ding D, Luo J, Glied S. Rural-Urban Disparities in the Uptake of New Diabetes Medications. Diabetes Spectr Publ Am Diabetes Assoc. 2025;38(1):49\u201357. https:\/\/doi.org\/10.2337\/ds23-0075.","journal-title":"Diabetes Spectr Publ Am Diabetes Assoc"},{"key":"2431_CR111","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 13. Older Adults: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S277\u201396. https:\/\/doi.org\/10.2337\/dc26-S013","DOI":"10.2337\/dc26-S013"},{"key":"2431_CR112","unstructured":"Coming Soon. CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries | CMS [Internet]. https:\/\/www.cms.gov\/newsroom\/press-releases\/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries. Accessed 21 July 2026."},{"issue":"1","key":"2431_CR113","doi-asserted-by":"publisher","first-page":"sfaf350","DOI":"10.1093\/ckj\/sfaf350","volume":"19","author":"R Minutolo","year":"2026","unstructured":"Minutolo R, Ruotolo C, Conte G, Borrelli S. SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art. Clin Kidney J. 2026;19(1):sfaf350. https:\/\/doi.org\/10.1093\/ckj\/sfaf350.","journal-title":"Clin Kidney J"},{"issue":"5","key":"2431_CR114","doi-asserted-by":"publisher","first-page":"e2511559","DOI":"10.1001\/jamanetworkopen.2025.11559","volume":"8","author":"MF Zupa","year":"2025","unstructured":"Zupa MF, Rothenberger SD, Bauer JG, Zheng Y, Johnson AE, Kinnee E, et al. Geographic and Sociodemographic Factors and Receipt of Metabolic Disease Specialty Care. JAMA Netw Open. 2025;8(5):e2511559. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.11559.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2431_CR115","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1161\/CIR.0000000000001453","volume":"154","author":"WC Members","year":"2026","unstructured":"Members WC, Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, et al. 2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4):e50\u2013158. https:\/\/doi.org\/10.1161\/CIR.0000000000001453.","journal-title":"Circulation"},{"issue":"2","key":"2431_CR116","doi-asserted-by":"publisher","first-page":"102575","DOI":"10.1016\/j.jacadv.2025.102575","volume":"5","author":"D Do","year":"2026","unstructured":"Do D, Murugiah K, Sawano M, Goodwin Cartwright BM, Rodriguez PJ, Gratzl S, et al. FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide\/Tirzepatide in CVD Patients With Overweight\/Obesity. JACC Adv. 2026;5(2):102575. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102575.","journal-title":"JACC Adv"},{"issue":"2","key":"2431_CR117","doi-asserted-by":"publisher","first-page":"e005546","DOI":"10.1136\/bmjdrc-2025-005546","volume":"14","author":"J German","year":"2026","unstructured":"German J, Huang WA, Brucker A, Daniel K, Halpern D, Bhavsar N, et al. Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c. BMJ Open Diabetes Res Care. 2026;14(2):e005546. https:\/\/doi.org\/10.1136\/bmjdrc-2025-005546.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2431_CR118","unstructured":"Food US, Administration D. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize [Internet]. US Food Drug Adm. FDA; 2026. https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize. Accessed 15 Sept 2026."},{"issue":"8","key":"2431_CR119","doi-asserted-by":"publisher","first-page":"bvaf084","DOI":"10.1210\/jendso\/bvaf084","volume":"9","author":"N Sood","year":"2025","unstructured":"Sood N, Garg R. Global Rise of Compounded Weight-Loss Medicines: A Worrisome Trend. J Endocr Soc. 2025;9(8):bvaf084. https:\/\/doi.org\/10.1210\/jendso\/bvaf084.","journal-title":"J Endocr Soc"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02431-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:59:34Z","timestamp":1791367174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02431-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2431"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02431-y","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"25 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Large language models were used to assist data extraction and risk-of-bias assessment, as described in the Methods and Supplement. All LLM-generated outputs were independently checked against the source articles by human reviewers and corrected as needed; no LLM output was accepted without human validation. AI-assisted improvements may include wording and formatting changes to the texts, but do not include generative editorial work and autonomous content creation.","order":2,"name":"Ethics","label":"Use of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":3,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"108"}}